Changes in Hong Kong stocks | Kangfang Biotech (09926) opened more than 4% higher, and research results related to evosil compared with pabolizumab were released at the WCLC conference

The Zhitong Finance App learned that Kang Fang Biotech (09926) opened more than 4% higher. As of press release, it rose 4.49% to HK$94.35, with a turnover of HK$13.5864 million.

^{According to news, according to Kang Fang's official Weibo news, at the 2026 World Lung Cancer Conference (WCLC) hosted by the International Association for Lung Cancer Research (IASLC), the company pioneered the global immunization 2.0 cornerstone drug evossi (trade name: edafang®). Compared with pabolizumab, first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with positive PD-L1 expression (PD-L1 TPS ≥ 1%) (TPS ≥ 1%) (HarmonI)} 2/AK112-303) significant positive OS results were released.

The research results were selected as an oral report by the conference as Late-Breaking Abstract (LBA), and selected for this year's WCLC official press release plan. Up to now, Evosi has obtained both positive OS and PFS results in multiple phase III clinical trials of head-to-head comparison PD-1/L1 therapy, and has gradually expanded into major solid tumors other than lung cancer.